The National Center for Cancer Research (CNIO) in Spain has ruled out the patent relating to a potential treatment for pancreatic cancer proposed by Mariano Barbacid. This decision was made due to the patent's lack of sufficient novelty and inventive step, which are critical criteria for patentability. Barbacid's claims that he could develop a stable cure for one of the deadliest forms of cancer garnered attention and financial support, raising 3.5 million euros through his company, Vega Oncotargets, which he announced shortly after the CNIO's decision.

The patent application was officially declined by the CNIO at the end of 2023, just before Barbacid's venture began in April 2024. This timing has stirred discussions in the scientific community about the viability and legitimacy of Barbacid's approach to pancreatic cancer treatment. The CNIO's decision and internal documents obtained by El Mundo indicate that the European Patent Office communicated similar concerns regarding the patent's robustness, casting a shadow over Barbacid's ambitious plans that have recently been promoted through various media platforms.

Barbacid, known for his contributions to cancer research, faces an uphill battle as he seeks to validate his proposed treatment amidst growing scrutiny. If his work proceeds without the validation of a patent, it could influence his ability to attract further investment and support for his research. The case highlights the intersection of scientific innovation and intellectual property, and the challenges faced by researchers in translating their findings into commercially viable treatments.